Stop chasing leads that won’t stand up to wet-lab validation. Whether you are building a lead or auditing a new investment, we provide the deep chemical expertise and computational power you need to move forward with certainty and conviction.
Computational Therapeutics Discovery LLC is a specialized computational chemistry consulting company focused on streamlining early-stage drug discovery through advanced molecular modeling and in-depth computational insights.
We bridge the gap between complex data and actionable results for biotech and pharmaceutical partners, CROs, and Venture Capital firms.
Accelerate Your Discovery Programs
Stop losing months to lead optimization loops. We provide computational chemistry and ML services across all stages of the drug discovery process to identify high-conviction hits that actually translate. Move your program from a digital design to an IND-ready candidate with total confidence.
Expand Your Capacity & Value
Enhance your wet-lab offerings with high-end computational support. We act as a seamless extension of your team, providing the "design" phase of the Design-Make-Test cycle for your clients. Together, we provide a holistic, target-to-compound solution.
De-Risk Your Technical Due Diligence
Invest with certainty. We look "under the hood" of potential investments to audit their computational workflows and validate their science. We help you separate truly transformative technology from scientific "smoke and mirrors."
At Computational Therapeutics Discovery LLC, we utilize cutting-edge technologies for computational drug discovery to provide a rigorous foundation for high-stakes decision-making. Whether we are supporting your internal hit identification and lead-optimization program, or performing technical due diligence for Venture Capital firms, our mission remains the same: to bridge the gap between computational claims and biological reality. By translating complex molecular data into actionable evidence, we help our partners validate scientific potential and focus resources on the most viable therapeutic paths.
Leverage giga-scale virtual screening to explore ultra-large chemical space beyond the reach of traditional VS. We utilize a proprietary combination of physics-based methods with ML/AI architectures to screen billions of molecules, identifying novel scaffolds that are both chemically tractable and enriched for experimental hit rates.
Evaluate the affinity of your new designs using accurate Free Energy Perturbation (FEP) calculations. We provide "gold-standard" RBFE binding affinity predictions to prioritize compounds for synthesis, significantly reducing "make-test" cycles in your lead optimization efforts.
Overcome the limitations of static structures of biomolecules by simulating their dynamic behavior. We employ advanced molecular dynamics (MD) and structure prediction to capture rare conformational states and induced-fit effects, ensuring your molecules are designed for the complexities of a moving, living system.
De-risk your drug discovery pipeline with precision molecular docking. We provide high-fidelity ligand-target structural models, allowing you to prioritize your most promising compounds and accelerate your hit-to-lead optimization through actionable insights into binding modes, interactions, and stability.
Optimize for success from the first iteration. Our predictive ADMET modeling provides you with insights into the metabolic stability, permeability, and safety profiles of your compounds, ensuring you advance only the most promising candidates and reduce late-stage attrition long before costly synthesis and experimental validation begins.
Harness data-driven insights to navigate and optimize complex chemical space. We utilize sophisticated informatics to support your hit identification and hit to lead efforts. Our approach maximizes molecular novelty and diversity while ensuring your candidates maintain favorable drug-like properties.
Streamline the transition from in silico discovery to experimental validation through our curated network of premier CRO partners and consultants. By orchestrating the entire discovery cycle, from target nomination and giga-scale screening to chemical synthesis and in vitro assays, we ensure that computational insights are rapidly translated into validated experimental results, providing a unified path to your next clinical candidate.
Quantify the "druggability" of your targets before committing significant capital. We perform extensive structural and pocket analyses to assess ligandability and tractability, helping you prioritize the most promising biological pathways with a clear-eyed view of the technical risks and competitive landscape.
We begin with a deep-dive technical consultation to align on your therapeutic goals. By discussing your program’s specific challenges together, we ensure the project is designed to address the unique biological hurdles your target faces.
Our team then develops a tailored project proposal outlining the optimal computational methodologies and rigorous validation steps. We review this roadmap together to ensure the scope, milestones, and deliverables are perfectly aligned with your internal timeline.
Our team executes the discovery phase, leveraging proprietary workflows to translate complex molecular data into clear, actionable evidence. The firm then presents the results with the transparency and depth required for high-stakes decision-making.
We evaluate the findings together to determine the most viable path forward. Whether the next step involves wet-lab validation or lead refinement, we ensure you have a definitive foundation for your next developmental milestone.
Great discovery happens at the intersection of innovative physics and actionable strategy. Our firm is dedicated to shortening the path from in silico hypothesis to experimental truth. If you are ready to accelerate your timeline and optimize your lead discovery process, reach out for a technical briefing. Let’s explore what we can achieve together.
© Computational Therapeutics Discovery LLC. All rights reserved
